Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Computerized Program (Neuroplasticity-Based Cognitive Remediation) for the Treatment of Chemotherapy Related Cognitive Impairment in Patients with Breast, Colon, Lymphoma, or Ovarian Cancer

Multiple Cancer Types

This trial studies how well a computerized program called neuroplasticity-based cognitive remediation works for the treatment of chemotherapy related cognitive impairment in patients with breast, colon, lymphoma, or ovarian cancer. There are few if any treatments shown to be effective in improving thinking and functioning in patients with attention and memory problems related to cancer treatment. This may leave patients vulnerable to loss of independence and functioning, and to developing depressive symptoms. Neuroplasticity-based cognitive remediation may help to improve thinking, functioning, and depressive symptoms in patients with breast, colon, lymphoma, or ovarian cancer.
Breast, Colon, Lymphoma, Ovarian
N/A
Newhouse, Paul
NCT04230863
VICCSUPP1936

Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

Breast

This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability of intravenous balixafortide given with eribulin versus eribulin alone in the treatment of HER2 negative, Locally Recurrent or Metastatic Breast Cancer.
Breast
III
Mayer, Ingrid
NCT03786094
VICCBRE1947

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Hematologic

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Hematologic
III
Satyanarayana, Gowri
NCT03394365
VICCBMT1875

Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab

Hematologic

This is a multicenter, open label, single-arm, phase 3 study to assess the efficacy and safety of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Hematologic
III
Satyanarayana, Gowri
NCT03392142
VICCBMT1876

Early Onset Pulmonary Events in Patients with Non-Small Lung Cancer or Other Cancers Taking Brigatinib or Other TKIs

Multiple Cancer Types

This phase II trial studies early onset pulmonary events in patients with non-small lung cancer and other cancers taking brigatinib or other TKIs. Severe side effects, including trouble breathing, coughing, pneumonia, and inflammation of the lungs (pneumonitis), have been seen in patients taking brigatinib. This study is being done to watch patients taking brigatinib and compare that experience with patients taking other drugs that also target ALK or ROS1 to study how often events like these occur. This study is also being done to observe patients who stopped brigatinib temporarily because of a suspected early onset pulmonary event, but then restarted brigatinib at the same dose to assess what experience they have.
Lung, Non Small Cell
II
Horn, Leora
NCT03389399
VICCTHO1885

Integrating Comprehensive Precision Tobacco Treatment for Patients with Cancer

Miscellaneous

Miscellaneous
N/A
Pietenpol, Jennifer
VICCTHO1886

A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Head/Neck

This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining CDX-3379 and cetuximab. The study will enroll patients with advanced head and neck squamous cell carcinoma who have previously received cetuximab and progressed.
Head/Neck
II
Gibson, Mike
NCT03254927
VICCHN1891

Trastuzumab, Vinorelbine Tartrate, and Avelumab with or without Utomilumab in Treating Patients with HER2-Positive Metastatic Breast Cancer

Breast

This phase II trial studies the how well trastuzumab, vinorelbine tartrate, and avelumab with or without utomilumab work in treating patients with HER2-positive breast cancer that has spread to other parts of the body. Immunotherapy with monoclonal antibodies, such as trastuzumab, avelumab, and utomilumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as vinorelbine tartrate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving trastuzumab, vinorelbine tartrate, and avelumab with or without utomilumab may work better in treating patients with breast cancer.
Breast
II
Abramson, Vandana
NCT03414658
VICCBRE1893

Capecitabine and Radiation Therapy after Surgery in Treating Patients with Non-Metastatic Invasive Breast cancer

Multiple Cancer Types

This phase I trial studies how well capecitabine and radiation therapy after surgery work in treating patients with invasive breast cancer that has not spread to other places in the body. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving capecitabine and radiation therapy together may kill more tumor cells in patients with invasive breast cancer compared to capecitabine or radiation therapy alone.
Breast, Phase I
I
Chak, Bapsi
NCT03958721
VICCBREP1898

A Study of ZN-c5 in Subjects With Breast Cancer

Multiple Cancer Types

This is a Phase 1 / 2, open-label, multicenter, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZN-c5 administered orally in subjects with advanced estrogen receptor positive, human epidermal growth factor receptor 2 negative (ER+ / HER2-) breast cancer. ZN-c5 will be evaluated both as monotherapy and in combination with palbociclib (IBRANCE®).
Breast, Phase I
I/II
Abramson, Vandana
NCT03560531
VICCBREP1899

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: